POLA1 and diffuse large B-cell lymphoma: The phase III POLARIX trial (NCT03274492) compared Pola-R-CHP with R-CHOP in previously untreated, high-risk DLBCL patients, demonstrating a statistically significant improvement in progression-free survival (PFS) for the polatuzumab-containing regimen (2-year PFS 76.7% vs. 70.2%) and a significant reduction in the risk of disease progression, relapse, or death (62).